The New Parsum IPP-80 In-Line Particle Sizing Probe: Robust, Trouble Free Granulation Monitoring
The new Parsum IPP-80 probe from Malvern Instruments brings easy to integrate in-line particle size measurement for efficient process monitoring and control. Suitable for powders, pellets and granules the new probe enables the real-time monitoring of agglomeration, coating and granulation processes. The resulting data provide a secure basis for pilot plant studies, process optimization and control. A robust, sanitary design delivers long-running operation with minimal attention and includes in-built self-diagnostic tools that ensure data quality.
For many pharmaceuticals, particle size is a performance defining characteristic. During granulation, for example, control of particle size may be vital, to ensure the production of granules that meet the requirements of subsequent processing steps and/or deliver the required performance in a finished product. In-line PSD measurement enables robust process monitoring and control. In the pharmaceutical industry these capabilities support the application of QbD, scoping of the Design Space and the development of continuous manufacturing in line with recent FDA guidance.
The Parsum IPP-80 inline probe provides continuous particle size and size distribution data, via the technique of spatial filter velocimetry. Measuring in the range of 50 µm to 6000 µm the probe is able to robustly analyse powders, as well as pellets and large granules. It has been fully optimised to meet the rigors of the process environment and has no moving parts or user-accessible components. Extremely stable optics mean that the probe is resistant to the effects of vibration and requires no manual alignment. The software includes a range of diagnostic features for measurement verification and self-diagnosis to ensure trouble-free operation and safeguard data quality. The Parsum IPP-80 has been specified for use in an environment where hygiene is a priority and has a sanitary stainless steel design that is easy to clean with any conventional cleaning agent. It is ATEX certified for Zone 0/20 operation.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.